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Summary Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental
condition characterised by inattention, impulsivity and hyperactivity; it is frequently co-morbid
with anxiety and conduct disorders, sleep perturbation and abnormal consummatory behaviours.
Recent studies have implicated the neurosteroid-modulating enzyme steroid sulfatase (STS) as a
modulator of ADHD-related endophenotypes. The effects of steroid sulfatase deficiency on
homecage activity, feeding/drinking behaviours, anxiety-related behaviours (assayed in light-
dark box and open field paradigms), social dominance and serum steroid hormone levels were
determined by comparing 40,XY and 39,XY*O mice. Subsequently, mice administered the steroid
sulfatase inhibitor COUMATE acutely were compared to vehicle-treated mice on behavioural tasks
sensitive to enzyme deficiency to dissociate between its developmental and ongoing effects.
39,XY*O mice exhibited heightened reactivity to a novel environment, hyperactivity in the active
phase, and increased water (but not food) consumption relative to 40,XY mice during a 24 h
period; the former group also demonstrated evidence for heightened emotional reactivity. There
was no difference in social dominance between the 40,XY and 39,XY*O mice. COUMATE adminis-
tration had no effect on homecage activity, water consumption or anxiety measures in the open
field. 39,XY*O mice exhibited significantly lower dehydroepiandrosterone (DHEA) serum levels
than 40,XY mice, but equivalent corticosterone levels. Together with previous data, the present
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results suggest that steroid sulfatase may influence core and associated ADHD behavioural
endophenotypes via both developmental and ongoing mechanisms, and that the 39,XY*O model
may represent a useful tool for elucidating the neurobiological basis of these endophenotypes.
# 2011 Elsevier Ltd. 
222 S. Trent et al.
Open access under CC BY license.1. Introduction
Attention Deficit Hyperactivity Disorder (ADHD) is a common
neurodevelopmental disorder characterised by inattention,
impulsivity and hyperactivity and affecting 3—7% of the
school-age population (Faraone et al., 2003; Thapar et al.,
2005). In a significant proportion of cases, ADHD symptoms
may persist into adulthood with adverse consequences for
employability, social interactions, and substance abuse (Able
et al., 2007). ADHD is often co-morbid with other disabling
conditions including conduct disorder (typified by heightened
aggression) and anxiety disorders (Cormier, 2008).
As ADHD is diagnosed between 4 and 6 times more fre-
quently in boys than in girls, sex-linked genes have been
implicated as modulators of risk (Holden, 2005). Based on
work in mouse models, the STS gene (which encodes the
enzyme steroid sulfatase) was proposed as a novel ADHD
candidate (Davies et al., 2007); in mice Sts is located within
the pseudoautosomal region of the sex chromosomes,
whereas its human orthologue resides within the X-specific
region at Xp22.3. The function of steroid sulfatase is to
cleave sulfate groups from steroid hormones (including dehy-
droepiandrosterone sulfate, DHEAS) in order to alter their
biological activity (Reed et al., 2005); in the brain, sulfated
and non-sulfated steroids can influence the function of GABAA
and NMDA receptors, and may exert distinct effects (Com-
pagnone and Mellon, 2000). Both DHEAS, and its non-sulfated
form DHEA, are negative modulators of the GABAA receptor,
and positive modulators of the NMDA receptor (Yadid et al.,
2010).
Work in humans has shown that individuals with deletions
encompassing STS (or with inactivating mutations within the
gene) are at elevated risk of developing ADHD (Kent et al.,
2008) and that STS is expressed in regions of the developing
brain relevant to ADHD pathology (Stergiakouli et al., 2011).
Moreover, STS polymorphisms are associated with: (i) vulner-
ability to developing the disorder (Brookes et al., 2008), (ii)
cognitive function in ADHD (Stergiakouli et al., 2011) and (iii)
altered gene expression in the healthy brain (Brookes et al.,
2010). Finally, it has previously been suggested that levels of
systemic DHEA (the non-sulfated form of DHEAS), but not
another steroid hormone (cortisol), are lower in individuals
with ADHD (Wang et al., 2011b) and that methylphenidate
may partially exert its therapeutic effect in ADHD subjects by
normalising DHEA levels (Maayan et al., 2003; Wang et al.,
2011a).
Through comparing wildtype to mutant 39,XY*O mice
(which lack the Sts gene but no other known genes as a
consequence of end-to-end fusion of the X and Y chromosomes
(Odorisio et al., 1998)), we have shown that Sts gene-deletion
results in impaired attention; inhibition of steroid sulfatase in
wildtype male mice with the specific inhibitor COUMATE reca-
pitulated this deficit, suggesting that the enzyme was influen-
cing attention via its ongoing function (Davies et al., 2009). We
also reported that neither Sts deletion, nor COUMATE admin-
istration, appeared to influence locomotor activity. However,our previous analysis was sub-optimal in that activity was
assayed using a crude measure (beam breaks) over a short
timeframe (1 h) during the day (i.e. non-active phase), and in a
different environment to the homecage of the mice (Davies
et al., 2009). Here, we assessed locomotor activity in 39,XY*O
and wildtype mice in a more sophisticated manner by con-
tinuously tracking individuals’ movements in a homecage-like
environment over an extended period. ADHD subjects have
been reported to show altered novelty-seeking behaviour (Cho
et al., 2009; Purper-Ouakil et al., 2010), perturbed circadian
rhythm and sleep disorders (Walters et al., 2008; Chiang et al.,
2010), and abnormalities in consummatory behaviours (Cor-
tese et al., 2007; Quinn, 2008). Our homecage experiment also
enabled us to assay reactivity to a novel environment, pro-
vided a crude index of the sleep-wake cycle and allowed us to
measure patterns of food and water consumption. As anxiety
disorders are comorbid with ADHD in up to 40% of cases
(Spencer, 2006), we also sought to compare anxiety-related
behaviours in 39,XY*O and wildtype mice using two well-
defined behavioural paradigms: the light-dark box and the
open field (Ramos, 2008; Milner and Crabbe, 2008). Finally,
given previous evidence for heightened aggression in 39,XY*O
mice (Davies et al., 2009), and suggestions that ADHD school-
children are both more likely to be bullies, and to be bullied
themselves (Holmberg and Hjern, 2008), we directly com-
pared social dominance in the two groups using the tube test
(Lindzey et al., 1961). Aggression is often employed in social
animals such as mice as a mechanism through which to main-
tain social hierarchies (Miczek et al., 2004). As in our previous
study (Davies et al., 2009), to ascertain whether behavioural
differences between Sts gene-deletion and wildtype mice
were due to the developmental or ongoing effects of steroid
sulfatase loss, we administered the specific steroid sulfatase
inhibitor COUMATE to wildtype mice; this drug has been shown
to attenuate brain steroid sulfatase activity by 70% 24 h after
administration (Nicolas et al., 2001). Finally, given the results
of steroid hormone analyses in subjects with ADHD and neu-
rotypical controls, we assayed systemic levels of DHEA and
corticosterone (the main glucocorticoid in rodents) in our
wildtype and mutant mice.
2. Methods
2.1. Subjects for behavioural experiments
39,XY*O mutant and 40,XY wildtype mice were bred at MRC
National Institute for Medical Research (NIMR), London.
39,XY*O mice were produced from three crosses: (i) 39,XPafO
x 40,XY*, (ii) 39,XPafO x 39,XY*O, and (iii) 40,In(X)Paf/X x
40,XY*. Paf is an X-linked mutation involving a small inversion
spanning the pseudoautosomal boundary which gives rise to a
‘patchy fur’ phenotype in heterozygous females and males
(Korobova et al., 1998), In(X) is an X chromosome containing
a large paracentric inversion (Evans and Phillips, 1975) and Y*
is a Y chromosome that has been hijacked by a non-Y cen-
tromere attached distal to the pseudoautosomal region and
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XY* chromosome that also lacks Sts (Eicher et al., 1991;
Burgoyne et al., 1998). 39,XY*O males could be identified
though a combination of checking gonadal type, checking for
the presence of patchy fur between postnatal days 7—10, and
polymerase chain reaction (PCR) for the Sts gene from tail
biopsy at weaning (primer sequences: 50-GCTCGCTGACAT-
CATCCTC-30 and 50-CACCGATGCCCAGGTCGTC-30; for detailed
PCR methods see Davies et al., 2009). 40,XY wildtype males
were generated from 40,XY  40,XX crosses. Care was taken
to keep the genetic backgrounds of the crosses equivalent
(i.e. predominantly that of the MF1 albino strain (NIMR
colony)) but with two C3H strain-derived factors which
enable fertility of 39,XY*O males; also, the 40,XY males carry
a Y chromosome derived from the LTstrain from which the Y*
chromosome originated. 36 40,XY wildtype mice and 19
39,XY*O mice were transferred to Cardiff University for
behavioural testing. 48 male MF1 mice (3 months) were
obtained from Harlan, UK for the pharmacological assays.
2.2. Animal husbandry
In Cardiff, mice from NIMR were treated with Baytril and
Norodine-24 antibiotics for one month in a negative-pressure
isolator to cure a Pasteurella pneumotropica infection prior
to release onto the open racks. These mice were then housed
in a holding room maintained at 21  2 8C and 50  10%
humidity, with a 12 h light-dark cycle (lights on at 0700 h),
either singly (due to the tendency of 39,XY*O mice to fight) or
in groups of up to three with mice of the same karyotype.
Behavioural testing in 40,XY and 39,XY*O mice took place
between the ages of 3—9 months. Mice for the pharmacolo-
gical study were housed in the same holding room (4 mice per
cage) and were tested between the ages of 3—6 months. Mice
were allowed ad libitum access to food and water throughout
behavioural testing. Animals were treated in accordance
with the Animal (Scientific Procedures) Act (United Kingdom,
1986). All efforts were made to minimize animal suffering, to
reduce the number of animals used, and to utilize alterna-
tives to in vivo techniques, if available.
2.3. Drug administration
Mice were administered either vehicle (0.5% methylcellu-
lose, 0.9% NaCl in distilled water, PO) or COUMATE (10 mg/kg
in the same vehicle PO, COUMATE synthesised according to
Nicolas et al., 2001) 24 h prior to behavioural testing.
2.4. Homecage behavioural analysis
39,XY*O (n = 19) and 40,XY mice (n = 25) were tested using a
battery of ‘Phenotyper’ homecages (Noldus Information
Technology) (30 cm  30 cm  35 cm (height)) for a 24 h
period coincident with one light-dark cycle in the holding
room (lights on for 12 h, lights off for 12 h), with behavioural
testing starting between 0700 h and 1000 h. Mice were
housed singly for the testing period, and the karyotypes were
pseudorandomly assigned to the different homecages to
negate any systematic order or homecage effects. Each
homecage contained a perspex shelter, a running wheel, a
water bottle connected to a lickometer and a food hopper,and was lined with clean absorbent black paper (Supplemen-
tary Fig. S1A). The top-unit of each cage housed an infra-red
sensitive camera to continuously record the position of the
mouse and an infra-red light source providing constant, even,
illumination of the cage floor. Tracking and data recording
was performed using EthoVision XTsoftware (Noldus Informa-
tion Technology) running on a high specification personal
computer (Dell, UK). Data were recorded for 8 bins, each
of 3 h duration. The tracking arena was sub-divided into 5
zones: running wheel, shelter, food zone, drinking zone and
arena floor (Supplementary Fig. S1B). The main output mea-
sures were: total distance travelled in the tracking arena,
time spent in each zone, number of rotations of the running
wheel, and number of licks of the water bottle spout. At the
end of the test session, total volumes of water and weight of
food consumed were measured. The apparatus was thor-
oughly cleaned with 1% acetic acid between mice.
Behaviourally naı¨ve mice for the pharmacological study
(Vehicle: n = 12, COUMATE: n = 12) were tested in the same
homecages, using a modified protocol: these mice were run in
the light for 3 h, and in the dark for 12 h, with testing
commencing between 1600 and 1700 h. This protocol ensured
that mice had opportunity to habituate to the apparatus, and
that the onset of the dark phase occurred 24 h after vehicle/
COUMATE administration. Data was recorded for 15 bins,
each of 1 h duration. Identical output measures were
recorded as for the genetic study. The apparatus was thor-
oughly cleaned with 1% acetic acid between mice.
2.5. Anxiety tests
After homecage monitoring, 39,XY*O (n = 19) and 40,XY mice
(n = 25) were tested in the light-dark box followed, five days
later, by testing in the open field. Behaviourally naı¨ve MF1
male mice for the pharmacological study (Vehicle: n = 12,
COUMATE: n = 12) were tested on the open field only.
2.6. Light-dark box
The apparatus consisted of two adjacent perspex boxes (one
black and one white) of equal size (30 cm  30 cm  30 cm),
connected by a hole (7 cm  7 cm). The black (dark) box was
covered with a black perspex lid, whilst the white (light) box
was illuminated from above at 300 lux. Mice were placed at
the far end of the light box, and allowed to explore freely for
5 min. Test sessions were recorded to videotape via a camera
directly above the apparatus for later coding by researchers
blind to karyotype. The main behavioural measures recorded
were: latency to enter the dark box, time spent in each box,
number of transitions between the two boxes, number of
fecal boli deposited, and presence/absence of urine. Mice
were scored as being in a box once all four legs had entered
the box. The apparatus was thoroughly cleaned with 1%
acetic acid between mice. Mutant and control mice were
run in a pseudorandomised order between 1200 h and 1700 h.
2.7. Open field
The apparatus consisted of a large square perspex box with a
black floor and white sides of size (75 cm  75 cm  45 cm
(height)), illuminated from above at 300 lux. Mice were
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Test sessions were recorded to videotape via a camera
directly above the apparatus for later coding by researchers
blind to karyotype/drug treatment. During videotape analy-
sis, the arena was subdivided into quadrants, and into an
outer and an inner zone (60 cm  60 cm). The main beha-
vioural measures recorded were: latency to enter the inner
zone, time spent in each zone, number of quadrants entered,
number of rears, number of fecal boli deposited, and pre-
sence/absence of urine. Mice were scored as being in a zone
once all four legs had entered the zone. The apparatus was
thoroughly cleaned with 1% acetic acid between mice.
Mutant and control mice were run in a pseudorandomised
order between 1030 h and 1600 h.
2.8. Social dominance tube test
One 39,XY*O mouse and one 40,XY mouse (matched as closely
as possible for weight) were placed head first at opposite
ends of a clear plastic tube (33 mm internal diameter, 30 cm
length) and released simultaneously. The bout ended when
one mouse withdrew completely from the tube. The mouse
remaining in the tube was designated the winner, and the
retreating mouse the loser. Each pairing had three bouts, and
there were 19 separate pairings (57 bouts in total). The test
was run between 1400 h and 1700 h.
2.9. Steroid hormone analysis
Trunk blood was obtained between 1100 h and 1430 h from
adult (8—10 months) 40,XY (n = 7) and 39,XY*O (n = 6) mice
generated using the crosses described above and group-
housed in the Animal Unit at MRC National Institute for
Medical Research. Blood was collected in Microtainer Gold
tubes (BD Biosciences). Tubes were inverted 5 times, and left
for 30 min for clotting to occur. Serum was separated by
centrifugation at 14,000 rpm for 2 min, aliquoted into eppen-
dorfs and stored at 80 8C. Steroid hormone levels were
assayed from serum samples using ELISA kits (dehydroepian-
drosterone (DHEA), DRG International; corticosterone, Enzo
Biosciences) according to the manufacturer’s instructions,
with sample dilution as necessary and samples run in tripli-
cate (DHEA) or duplicate (corticosterone). For the DHEA
ELISA, cross reactivity was 100% for DHEA and <0.072% for
other related compounds; analytical sensitivity of the assay
was 0.108 ng/ml. For the corticosterone ELISA, cross reac-
tivity was 100% for corticosterone, 28.6% for deoxycorticos-
terone and <2% for other related compounds; analytical
sensitivity of the assay was 26.99 pg/ml. Standard curves
were determined using SigmaPlot 11.0 (Systat Software Inc.)
according to the hyperbolic decay curve defined by the
following equation: y = y0 + (ab/(b + x)) where y0, a and b
are constants. Sample outliers (i.e. values >2 standard
deviations below or above the group mean) were excluded
from the analysis.
2.10. Statistics
Statistics were analysed using SPSS 16.0 (IBM Corporation,
New York). Normal data were analysed by unpaired two-
tailed t-test/Two Way Repeated Measures ANOVA, withfactors of karyotype/drug treatment and timepoint.
Skewed data were transformed before parametric analysis
as appropriate. Where sphericity assumptions were violated
in Two Way ANOVA, Greenhouse-Geisser corrected degrees
of freedom values are presented. When ANOVA indicated an
interaction between karyotype/drug treatment and TIME-
POINT, post hoc pairwise comparisons were performed using
unpaired t-tests between each datapoint. Non-parametric
data were analysed by two-tailed Mann—Whitney U test.
Frequency data were analysed by two-tailed Fisher Exact
Test or x2 analysis. p-Values of 0.05 were regarded as
significant; for post hoc tests p-values were adjusted to
account for multiple testing. Data are reported as mean
values  standard error of the mean. Where appropriate,
effect sizes were calculated according to Cohen (1988) and
d values are presented. No differences were observed
between 39,XY*O mice with 39,XPafO or 40,In(X)Paf/X
mothers (n = 14 and n = 5 respectively), or between singly
and group-housed 39,XY*O mice (n = 12 and n = 7 respec-
tively) unless stated in the text.
3. Results
3.1. 39,XY*O mice are hyperactive and consume
more water (but not food) relative to 40,XY mice
Individual mouse tracking data showed that 39,XY*O mice
were more hyperactive than 40,XY mice during the initial 3 h
of homecage testing but not during the remainder of the light
phase; throughout the dark phase, 39,XY*O mice were 70%
more active than 40,XY mice (Cohen’s d = 0.86) (effect of
karyotype: F[1,42] = 5.92, p < 0.05, effect of karyoty-
pe  timepoint: F[3.87,42] = 4.00, p < 0.005, Fig. 1A). Con-
servative post hoc testing revealed a significant difference
between karyotypes 18—21 h after the onset of testing (cor-
rected p-value < 0.05). Analysis of a second, more variable,
measure of activity (number of running wheel revolutions)
also revealed 39,XY*O mice to be more active than their
wildtype counterparts (Cohen’s d = 0.64) (effect of karyo-
type: F[1,42] = 4.66, p < 0.05, Fig. 1B). 39,XY*O mice spent
significantly less time in the shelter than 40,XY mice across
all time bins (Cohen’s d = 0.97) (effect of karyotype:
F[1,42] = 9.41, p < 0.005, Fig. 1C).
39,XY*O mice drank a significantly greater volume of water
per unit bodyweight than 40,XY mice (0.22  0.01 ml/g vs.
0.18  0.01 ml/g respectively, t[42] = 2.62, p < 0.05,
Cohen’s d = 0.81). This is consistent with a strong trend
towards a greater degree of licking behaviour in 39,XY*O
mice (total licks: 4795  1292 vs. 2005  551,
t[24.5] = 1.96, p = 0.06) and with these mice spending sig-
nificantly more time in the drinking zone (124  33 s vs.
37  12 s, t[20.4] = 3.17, p < 0.005, Cohen’s d = 0.98). In
contrast, there was no difference between 39,XY*O and 40,XY
mice with respect to overall food consumption per unit
bodyweight (0.20  0.01 g/g vs. 0.24  0.04 g/g respec-
tively, t[27.7] = 1.00, p = 0.33), despite 39,XY*O spending
more time in the feeding zone (data not shown). In some
studies, food/water consumption are normalised to body-
weight0.75 to account for metabolic scaling (e.g. Doe et al.,
2009); this alternative analysis did not alter the pattern of
data (effect of karyotype on water consumption:
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Figure 1 Behaviour of 40,XY (n = 25) and 39,XY*O (n = 19) mice in automated homecages over a 24 h period (lights off after 12 h). (A)
39,XY*O mice showed heightened reactivity to the novel environment (0—3 h), and increased activity during the dark phase (12—24 h)
relative to 40,XY mice as indexed by lateral activity. *Corrected p-value <0.05 for post hoc comparison. (B) 39,XY*O mice made
significantly more revolutions in the homecage running wheels throughout the testing period relative to 40,XY mice. (C) 39,XY*O mice
spent significantly less time in the shelter throughout the testing period than 40,XY mice.
Behaviour in steroid-sulfatase deficient mice 225t[42] = 2.30, p < 0.05, effect of karyotype on food con-
sumption: t[27.5] = 1.14, p = 0.27). Drinking and feeding
patterns were similar between the two groups, with the
majority of consummatory behaviours occurring from the
onset to the end of the dark phase (data not shown).
3.2. 39,XY*O mice differ from 40,XY mice on
aspects of anxiety-related behaviour
In the light-dark box, 39,XY*O mice initially entered the dark
box from the light box significantly more rapidly than wild-
type mice (Cohen’s d = 0.67), and defecated/urinated to a
significantly greater extent (Table 1); singly housed 39,XY*O
mice urinated more frequently than group-housed 39,XY*O
mice (Fisher Exact Test, p < 0.05). 40,XY and 39,XY*O mice
did not differ with respect to a further measure of anxiety-
related behaviour i.e. time spent in the light box, nor with
respect to a measure of in-test activity, the number of
transitions between boxes (Table 1).
40,XY and 39,XY*O mice differed on the main measure of
anxiety-related behaviour in the open field, whereby the
latter group spent a significantly greater amount of time in
the outer zone (Cohen’s d = 0.68); 39,XY*O mice also took
longer to enter the inner zone from the outer zone (Table 1).Table 1 Anxiety-like profile in 40,XY and 39,XY*O mice.
Test and measure 40,XY (n = 25) 
Light-dark box
Latency to enter dark box (s) 47.8  7.8 
Time spent in light box (s) 113.6  11.4 
Transitions between boxes 9.0  1.3 
Fecal boli deposited 0.1  0.1 
Mice urinating/mice not urinating 0/25 
Open field
Latency to enter inner zone (s) 86.0  21.0 
Time spent in outer zone (s) 253.3  7.1 
Transitions between quadrants 36.0  4.4 
Rears 14.7  2.6 
Fecal boli deposited 1.9  0.4 
Mice urinating/mice not urinating 2/23 39,XY*O mice showed a strong, but non-significant, trend
towards increased defecation in this test, and an increased
rate of urination (Table 1). There was no significant differ-
ence between the two groups with respect to measures of
activity or exploration in the open field test (Table 1).
3.3. 39,XY*O and 40,XY mice do not differ in
their social dominance
Of 57 bouts in the tube test, 40,XY mice won 31, and 39,XY*O
mice won 26 (x2[1] = 0.28, p = 0.60). Heavier mice did not
win significantly more frequently than lighter mice irrespec-
tive of genotype (x2[1] = 0.28, p = 0.60); therefore, the fact
that 39,XY*O mice were lighter than 40,XY mice (41.2  0.7 g
vs. 44.6  0.4 g) is unlikely to confound the main result.
3.4. COUMATE-treated mice do not differ from
vehicle-treated mice with respect to locomotor
activity, water consumption or anxiety-related
measures
Although both vehicle and COUMATE-treated groups showed
the expected patterns of lateral activity (effect of timepoint,
F[4.2,92.8] = 21.15, p < 0.001), there was no effect of drug39,XY*O (n = 19) Significance level
28.3  4.5 t[37.4] = 2.17, p < 0.05
114.1  21.8 t[27.6] = 0.02, p = 0.99
8.8  1.7 t[42] = 0.06, p = 0.96
1.0  0.3 U = 139, p < 0.005
6/13 Fisher Exact Test, p < 0.005
133.1  27.0 t[42] = 1.40, p = 0.17
274.2  5.6 t[42] = 2.20, p < 0.05
32.4  4.2 t[42] = 0.57, p = 0.57
13.2  3.1 t[42] = 0.38, p = 0.71
3.1  0.5 U = 159.5, p = 0.06
4/15 Fisher Exact Test, p = 0.38
Table 2 Behavioural measures in the open field in mice treated with vehicle or the steroid sulfatase inhibitor COUMATE.
Test and measure Vehicle-treated (n = 12) COUMATE-treated (n = 12) Significance level
Open field
Latency to enter inner zone (s) 37.3  7.2 43.7  14.2 t[22] = 0.40, p = 0.69
Time spent in outer zone (s) 224.3  7.4 234.9  6.8 t[22] = 1.06, p = 0.30
Transitions between quadrants 45.9  3.4 41.1  4.4 t[22] = 0.87, p = 0.39
Rears 40.8  3.4 29.8  3.5 t[22] = 2.29, p < 0.05
Fecal boli deposited 1.7  0.5 2.1  0.5 U = 62.5, p = 0.59
Mice urinating/mice not urinating 2/10 2/10 Fisher Exact Test, p = 1.0
226 S. Trent et al.treatment (F[1,22] = 0.08, p = 0.77), nor any interaction
between drug treatment and timepoint
(F[4.2,92.8] = 0.41, p = 0.81). There was also no difference
in the total number of running wheel revolutions between
COUMATE and vehicle-treated mice (8730  1228 vs.
9864  1945 respectively, t[22] = 0.49, p = 0.63). During
homecage behavioural testing, COUMATE-treated mice did
not consume significantly more water per unit bodyweight
than vehicle-treated mice (0.18  0.03 ml/g vs.
0.16  0.02 ml/g respectively, t[22] = 0.40, p = 0.69), and
nor did they make significantly more licks (1176  377 vs.
649  122 respectively, t[22] = 1.38, p = 0.18). Vehicle and
COUMATE-treated mice did not differ with respect to anxi-
ety-related behavioural measures in the open field test
(Table 2).
3.5. 39,XY*O mice exhibit lower levels of serum
DHEA, but equivalent levels of corticosterone, to
40,XY mice
One outlier 40,XY mouse was excluded from each analysis.
Serum DHEA levels were significantly lower in 39,XY*O mice
than 40,XY mice (t[10] = 2.25, p < 0.05, Cohen’s d = 1.42),
whilst corticosterone levels did not differ between the two
groups (t[10] = 1.29, p = 0.23) (Fig. 2).
4. Discussion
This study investigated whether steroid sulfatase deficiency
could influence behavioural endophenotypes associated with
ADHD. The main finding was that 39,XY*O mice were hyper-
active relative to 40,XY mice upon exposure to a novel
environment and during the active phase. Consistent with
our previous data (Davies et al., 2009), 39,XY*O and 40,XY
mice were found to be equally active for the majority of the39,XY*O40,XY
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Figure 2 DHEA (A) and corticosterone (B) levels in serum olight phase. Importantly, given that isolation rearing may
elicit hyperlocomotion in adult mice (Koike et al., 2009), we
found no difference in activity profiles between singly and
group-housed 39,XY*O mice (Supplementary Fig. S2). It has
previously been reported that DHEA levels are lower in
individuals with ADHD than in neurotypical subjects, and
that serum DHEA(S) levels correlate inversely with the hyper-
activity subscale in ADHD patients (Strous et al., 2001; Wang
et al., 2011b). Therefore, we analysed steroid hormone
serum levels in 39,XY*O and 40,XY mice. We found that levels
of DHEA (but not corticosterone) were lower in the former
group; these data suggest some overlap between the phy-
siology of ADHD subjects and 39,XY*O mice, and support the
concept that low levels of systemic DHEA may be associated
with increased activity (Supplementary Fig. S3).
We also found that 39,XY*O mice consumed a greater
volume of water (but not food) during testing than 40,XY
mice; this dissociation suggests that the greater degree of
water consumption in 39,XY*O mice may not simply be a
function of their greater locomotor activity. Interestingly,
ADHD subjects have been reported to drink significantly more
water than typically developing individuals in a free-drinking
experiment, possibly as an osmo-regulatory mechanism
(Oades et al., 1998). The general patterns of activity and
consummatory behaviours in 39,XY*O and 40,XY mice over a
24 h period were similar, indicating that there were no gross
disturbances in the sleep-wake cycle of the former group.
However, more detailed assessment of circadian rhythms in
these mice might be performed over longer testing periods in
the future.
Data from two tasks assaying aspects of anxiety provided
converging evidence for enhanced anxiety-related beha-
viours in 39,XY*O mice relative to 40,XY mice. These data
are likely to specifically reflect group differences in anxiety
per se because: (i) in-test measures of activity/exploration
did not differ between groups, (ii) the groups showed equiva-39,XY*O40,XY0
2
4
6
8
10
12
14 (B)
f adult 40,XY (n = 6) and 39,XY*O (n = 6) mice (*p < 0.05).
Behaviour in steroid-sulfatase deficient mice 227lent homecage activity during the light phase (when tests were
performed), (iii) food/water consumption was equivalent
between groups during the light phase and (iv) most measures
were indifferent to whether the 39,XY*O mice were singly or
group-housed. It is possible that heightened anxiety-related
behaviour in the 39,XY*O mice could account for their loco-
motor hyper-reactivity to a novel homecage environment.
The pharmacological study indicated that acute inhibition
of the steroid sulfatase enzyme did not recapitulate the
effects of Sts gene deficiency on activity and anxiety-related
behaviour. Whilst this finding suggests that steroid sulfatase
may exert its influence on these phenotypes via neurodeve-
lopmental pathways rather than via ongoing effects on neu-
rosteroid metabolism, as COUMATE does not completely
inhibit steroid sulfatase activity, the latter possibility cannot
be completely discounted. We previously showed that acute
pharmacological manipulations targeting the steroid sulfa-
tase axis could influence aspects of attention in mice, and
therefore suggested that the enzyme’s ongoing activity was
important in this cognitive function (Davies et al., 2009).
Overall, our results indicate that steroid sulfatase may have
temporally dissociable effects on the distinct brain sub-
strates underlying attention and activity/anxiety.
We did not find any difference between 39,XY*O and 40,XY
mice in social dominance behaviour as assayed by the tube
test; hence, steroid sulfatase is unlikely to affect this beha-
vioural function. We previously reported that 39,XY*O mice
generally appeared more overtly aggressive than their 40,XY
counterparts (Davies et al., 2009); in the present experi-
mental cohort, a similar pattern of effects was observed
(Supplementary Table 1). Genetic data have implicated ster-
oid sulfatase in murine attack behaviours (Le Roy et al., 1999;
Mortaud et al., 2010) whilst acute inhibition of the enzyme
enhances aggression in mice (Nicolas et al., 2001). There-
fore, it may be worth following up these preliminary descrip-
tive findings in more quantitative analyses of intra-species
aggression (Roubertoux et al., 2005).
Humans with steroid sulfatase deficiency are at signifi-
cantly increased risk of developing inattentive subtype ADHD
(and possibly autism) relative to the general population (Kent
et al., 2008); a number of case studies have also reported
ADHD and autistic symptoms in steroid sulfatase-deficient
individuals (Thomas et al., 1999; Tobias et al., 2001; Doherty
et al., 2003). Our mouse data suggest that future behavioural
studies on these individuals should focus on activity and
anxiety phenotypes. Following our characterisation of atten-
tion deficits in 39,XY*O mice (Davies et al., 2009), we sub-
sequently identified a single nucleotide polymorphism
(rs17268988) within STS which was associated with inatten-
tive symptoms in ADHD boys (Stergiakouli et al., 2011). By
analogy, the present data suggest that STS polymorphisms
may be associated with activity, drinking behaviour and
anxiety endophenotypes in ADHD and autistic subjects.
Behavioural abnormalities in 39,XY*O mice presumably arise
due to the altered development/function of brain regions
where Sts is expressed (together with their associated circui-
try). In the murine brain, Sts is most highly expressed in the
cortex, hindbrain and thalamus (Compagnone et al., 1997). We
previously suggested that the attentional deficits observed in
39,XY*O mice could be due to altered function of the pontine/
basal forebrain cholinergic systems and/or to perturbed
GABAergic function in the subthalamic nucleus (Davieset al., 2009). Rodents with lesions affecting the basal forebrain
cholinergic system exhibit increased activity (Torres et al.,
1994; van der Staay et al., 2006; Moreau et al., 2008), and
heightened aggression (Bergvall et al., 1996), whilst both
subthalamic nucleus lesions (Baunez et al., 2002) and infusion
of the GABAA receptor agonist muscimol into this nucleus
(Williams and Herberg, 1987) induce hyperactivity in rodents.
Examination of these neuroanatomical systems in 39,XY*O mice
and steroid sulfatase-deficient humans may be informative
with a view to understanding how steroid sulfatase dysfunction
might impact upon ADHD-relevant endophenotypes.
In conclusion, we have shown that the 39,XY*O mouse,
which has some degree of construct validity as an ADHD
model, also exhibits a reasonable degree of face validity
(at least for a subset of individuals): notably inattention,
hyperactivity, heightened anxiety-related behaviours,
increased water consumption and lowered systemic levels
of DHEA but not corticosterone/cortisol. Investigations in the
39,XY*O mouse are therefore likely to elucidate the neuro-
biological underpinnings of several important behavioural
endophenotypes associated with ADHD (Gainetdinov, 2010).
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